The Society for Immunotherapy of Cancer (SITC) developed and published the first evidence-based consensus statement on tumor immunotherapy for the treatment of patients with cutaneous melanoma in Nature Reviews Clinical Oncology in 2013.

On Wednesday, May 30, 2018, SITC published an update in the Journal for ImmunoTherapy of Cancer (JITC), the society's open access, peer-reviewed online journal.

This updated consensus statement provides expert evidence-based recommendations for the use of immunotherapies including checkpoint inhibitor monotherapies and combinations, as well as oncolytic viruses, interferon-α2, and interleukin-2 in various disease stages and settings. This statement also includes recommendations for patient selection, sequencing or combination of therapies, using and screening for predictive biomarkers, managing adverse events, and selecting optimal clinical endpoints.

Learn more about immunotherapy treatment standards for melanoma in the recently updated in the SITC Cancer Immunotherapy Guidelines – Cutaneous Melanoma 2.0 manuscript.

SITC hosted a one-hour webinar on Monday, July 30, 2018, featuring members of the Cancer Immunotherapy Guidelines – Melanoma Subcommittee.

Click here to view the webinar on-demand.

Current Guideline and Algorithms

Online Update Available

Published May 30, 2018 in Journal for ImmunoTherapy of Cancer (JITC) as "An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0."

Updated July 27, 2018 – Melanoma treatment algorithms V 07.2018

Algorithm Update: Version 07.2018

Consensus management of microscopic single node disease (stage N1a – AJCC 7th; stage IIIA – AJCC 8th)

In light of new data concerning the availability of anti-PD-1 agents for the treatment of patients with stage N1a/IIIA melanoma, the subcommittee was re-polled to generate new consensus recommendations. These new consensus recommendations supersede the original recommendations in Sullivan et al. 2018 within the following sections

Paragraph 1 - ‘Consensus management of microscopic single node disease (stage N1a – AJCC   7th; stage IIIA – AJCC 8th)’

Updates in Version 07.2018 

1. Figure 2 and the corresponding figure legend have been updated with new polling results and consensus recommendations
   1. Order of therapeutic preference has been revised
   2. Anti-PD-1 agents nivolumab and pembrolizumab are now listed as options

Version 05.2018	Version 07.2018

Consensus management of unresectable stage III/IV melanoma with injectable lesions

In light of new data concerning efficacy of combination anti-PD-1 nivolumab + anti-CTLA-4 ipilimumab for the treatment of patients with unresectable stage III/IV melanoma, the subcommittee was re-polled to generate new consensus recommendations. These new consensus recommendations supersede the original recommendations in Sullivan et al. 2018 within the following sections

Updates in Version 07.2018 

1. Figure 4 and the corresponding figure legend have been updated with new polling results and consensus recommendations
   1. Introduction of new patient categories
      1. Patients with BRAF­-mutated disease and good performance status
      2. Patients with BRAF­-wild type disease and good performance status
   2.  Order of therapeutic preference has been revised in all patient categories
   3. Combination anti-PD-1 nivolumab + anti-CTLA-4 ipilimumab is now listed as an option for patients with poor performance status

Version 5.2018	Version 7.2018

Cancer Immunotherapy Guidelines Cutaneous Melanoma

subcommittee leadership

subcommittee members